Digest Network Come funziona
Network
/
Società
Ob
Non verificato

Oblique Therapeutics AB

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaFranchisingSanità

3 comunicati stampa

Guarda tutti i comunicati
22/10/2024
Farmaceutica
Sanità
Biologia
Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage
Fonte
Oblique Therapeutics AB
Emittente
PR News Wire
1.00
0
22/08/2024
Farmaceutica
Sanità
Economia
Brevetti, marchi e copyright
Biologia
Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target
Fonte
Oblique Therapeutics AB
Emittente
PR News Wire
1.00
0
18/06/2024
Farmaceutica
Information Technology
Telecomunicazioni
Sanità
Imprese
Organizzazione Aziendale
Economia
Franchising
Biologia
Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers
Fonte
Oblique Therapeutics AB
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0